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Abstract: 
Myocardial infarction (MI) is the leading cause of death worldwide and extensive 
research has therefore been performed to find a cure. Neuregulin-1 (NRG) is a growth 
factor involved in cardiac repair after MI. We previously described how biocompatible 
and biodegradable microparticles, which are able to release NRG in a sustained manner, 
represent a valuable approach to avoid problems related to the short half-life after 
systemic administration of proteins. The effectiveness of this strategy could be 
improved by combining NRG with several cytokines involved in cardiac regeneration. 
The present study investigates the potential feasibility of using NRG-releasing particle 
scaffold combined with adipose derived stem cells (ADSC) as a multiple growth factor 
delivery-based tissue engineering strategy for implantation in the infarcted myocardium. 
NRG-releasing particle scaffolds with a suitable size for intramyocardial implantation 
were prepared by TROMS. Next, ADSC were adhered to particle scaffolds and their 
potential for heart administration was assessed in a MI rat model. NRG was 
successfully encapsulated reaching encapsulation efficiencies of 92.58 ± 3.84 %. NRG 
maintained its biological activity after the microencapsulation process. ADSC cells 
adhered efficiently to particle scaffolds within a few hours. The ADSC-cytokine 
delivery system developed proved to be compatible with intramyocardial administration 
in terms of injectability through a 23-gauge needle and tissue response. Interestingly, 
ADSC-scaffolds were present in the peri-infarted tissue two weeks after implantation. 
This proof of concept study provides important evidence required for future 
effectiveness studies and for the translation of this approach. 
Keywords: Particle scaffold, PLGA Microparticles, ADSC, NRG-1, Myocardial 
infarction, Cardiac repair 
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1 Introduction: 
Cardiovascular diseases cause more than 17 million deaths each year according to 
the latest report of the World Health Organization (available in 
http://www.who.int/cardiovascular_diseases), constituting the greatest health risk in 
western countries [1]. Despite the advances in pharmacological treatment, a major 
improvement able to repair the massive loss of cardiomyocytes after a myocardial 
infarction (MI) has not yet been reached, heart transplantation being the only real option 
for severe cases. Due to this situation new approaches have been explored in the last 
few years [2-5]. One of these strategies is the use of growth factors (GF). GF are 
thought to benefit the damaged heart through direct effects in the myocardium and by 
stimulating and mobilizing progenitor cells [6]. However, GF protein  administration 
presents serious limitations due to their short in vivo half life, physical and chemical 
instability, and the low oral bioavailability of these macromolecules [7]. The use of drug 
delivery systems (DDS) that encapsulate GF might overcome these drawbacks. 
Microparticles (MP), one of these DDS, could protect proteins from degradation and 
ensure sustained release among time [8]. Recently, our group explored new therapeutic 
strategies for MI treatment, based on the use of polymeric MP that release different GF 
involved in cardiac angiogenesis and neovascularization [8-11]. Neuregulin-1 (NRG) 
deserves special attention in heart regeneration because it is involved in cardiac repair 
after MI [12]. This protein plays a crucial role in the adult cardiovascular system by 
inducing sarcomere membrane organization and integrity [13], cell survival [14, 15] and 
angiogenesis [16]. We recently proved that NRG-releasing MP promoted cardiac repair 
and improved cardiac performance [11]. NRG-releasing MP effectiveness could be 
improved by combining this protein with several other cytokines involved in cardiac 
regeneration. This could be achieved by preparing a polymer-based GF delivery system 
4 
 
that allows the release of multiple factors [6]. However, to date GF delivery systems 
have not demonstrated the ability to deliver cocktail of factors with distinct kinetics 
[17]. This aspect, besides the limitation that GF dose and timing are crucial for helping 
regeneration, makes it difficult to co-administer different GFs [6, 7]. The combination 
of NRG-releasing MP with cytokines secreted by stem cells (SC), capable of responding 
to the host environment, opens up a possible solution to that drawback. Moreover, MP 
possess many features that make them suitable for use as cardiac scaffolds. In particular, 
they are biodegradable, biocompatible, non-toxic and, importantly, they can provide 
structural support for cell survival and differentiation [18-24].  
Among the different SC sources, adipose-derived stem cells (ADSC) have shown 
promising results in cardiac repair [25-28]. They are good candidates for cell therapy 
studies because of their easy isolation from the stromal vascular fraction [29-32] and 
their extensive differentiation potential. In addition, ADSCs are able to secrete 
angiogenic and/or anti-apoptotic factors [33], such as granulocyte-macrophage colony 
stimulating factor (GM-CSF), vascular endothelial growth factor (VEGF), hepatocyte 
growth factor (HGF), fibroblast growth factor (bFGF), and transforming growth factor-
β (TGF-β) [31]. 
For all of these reasons, the primary purpose of this work was to investigate the 
potential feasibility of NRG-releasing particle scaffold combined with ADSC as a multi 
GF delivery-based tissue engineering strategy for the ischemic heart. To this end, NRG-
releasing delivery system was prepared using Total Recirculation One-Machine System 
(TROMS), a technique based on the multiple emulsion solvent evaporation method 
which is suitable for the encapsulation of labile molecules like cytokines and GFs [8, 
34]. We primarily investigated the physical characteristics of the particle scaffold such 
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as morphology or size. Then, NRG-releasing particle scaffolds were combined with 
ADSC and flow properties such as dispersability and injectability of the ADSC particle 
scaffold suspension were analyzed to avoid complications during their administration. 
The myocardial response to ADSC combined with NRG-releasing particle scaffold was 
finally evaluated using a MI rat model to ensure safety and biocompatibility 
requirements.  
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2.1 Materials 
Poly(lactic-co-glycolic acid) (PLGA) with monomer ratio (lactic acid/glycolic 
acid) of 50:50 Resomer® RG 503H (Mw: 34 kDa) was provided by Boehringer-
Ingelheim (Ingelheim, Germany). Polyethylene glycol (PEG; Mw: 400), human serum 
albumin (HAS), bovine serum albumin (BSA), dimethylsulfoxide (DMSO), 
carboxymethyl-cellulose, mannitol, polysorbate 80, sodium azide and rhodamine B 
isothiocyanate were provided by Sigma-Aldrich (Barcelona, Spain). Dichloromethane 
and acetone were obtained from Panreac Quimica S.A. (Barcelona, Spain). 
Poly(vinylalcohol) (PVA) 88% hydrolyzed (Mw: 125,000) was obtained from 
Polysciences, Inc. (Warington, USA). Collagen I of rat tail 3mg/mL, Minimum 
Essential Medium Alpha (α-MEM) Medium, 0.05% Trypsin-EDTA, Heat inactivated 
Fetal Bovine Serum (FBS), Phosphate Buffered Saline pH 7.2 (PBS) and Dulbecco´s 
Modified Eagle Medium (DMEM) were provided by Gibco-Invitrogen (Carlsbad, CA, 
USA). ADSC cells were obtained from inguinal adipose tissue of male Sprague-Dawley 
transgenic rats. H9c2 cells were provided by ATCC. Poly D-Lysine 1 mg/ml (PDL) was 
provided by Merck-Millipore (Darmstadt, Germany). rh Neuregulin-1b-iso (NRG) was 
provided by EuroBioSciences (Friesoythe, Germany). 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS) was purchased 
from Promega (Madison, USA). Goat polyclonal anti-human NRG-1 antibody (sc-1793) 
and horseradish-peroxidase-conjugated donkey anti-goat IgG (sc-2020) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).  
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2.2 Preparation of NRG-releasing particle scaffold 
NRG-releasing PLGA particle scaffolds were prepared by the emulsion solvent 
evaporation method using TROMS as previously described [11] with minor 
modifications. In order to obtain batches with the defined particle size the following 
TROMS parameters were adjusted: pumping flow, recirculation times to obtain both 
W1/O and W1/O/W2 emulsions, and inner diameters of the needles used to prepare the 
emulsions. Briefly, the organic phase (O) composed of 100 mg of PLGA dissolved in 4 
ml of a dichloromethane/acetone mixture (ratio 3:1) was injected into the inner aqueous 
phase (W1) containing 200 μg of NRG, 5 mg of HSA and 5 μl of PEG 400 dissolved in 
200 μl of phosphate-buffered saline (PBS pH 7.9). Next, the inner emulsion (W1/O) was 
recirculated through the system under a turbulent regime maintained by a pumping flow 
through a needle. After this homogenization step, the W1/O emulsion was injected into 
the outer aqueous phase (W2) composed of 20 ml of a 0.5% w/v PVA solution. The 
turbulent injection through a second needle resulted in the formation of a multiple 
emulsion (W1/O/W2), which was allowed to circulate through the system to become 
homogeneous. The multiple emulsion was stirred for 3 h to allow solvent evaporation. 
Particle scaffolds were washed three times with ultrapure water by consecutive 
centrifugations at 4 °C (20,000×g, 10 min). NRG-releasing particle scaffolds were 
lyophilized for 48h without cryoprotective agents (Virtis Genesis 12 EL, Gardines, 
NY). The conditions of freeze drying were -50ºC to +15ºC over 2 days. After complete 
lyophilization, the vials were sealed under vacuum and stored at -20°C until use. 
Unloaded particle scaffolds were prepared in the same manner without adding NRG. 
For fluorescence-labeled formulation, rhodamine B isothiocyanate (0.5 mg/mL) was 
added to the inner aqueous phase and particle scaffolds were prepared as described. 
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2.3 NRG-releasing PLGA particle scaffold characterization 
2.3.1 Particle size analysis 
The mean particle size and size distribution were examined by laser 
diffractometry using a Mastersizer® (Malvern Instruments, Malvern, UK). Particle 
scaffolds were dispersed in ultrapure water and analyzed under continuous stirring. The 
average particle size was expressed as the volume mean diameter in micrometers. 
2.3.2 Drug content 
The amount of NRG encapsulated in the particle scaffold was determined by 
dissolving 0.5 mg of lyophilized loaded particles in 25 µL of DMSO, and was 
quantified using western blot. After electrophoresis and transference, the membranes 
were blocked with 5% nonfat dried milk in TBS plus 0.05% Tween 20 for 2 h, then 
incubated overnight at 4ºC with primary antibody goat IgG-NRG-1β-IGGF2 (sc-1793) 
1:50. After several washes the membranes incubated with antigoat IG-HRP (sc-2020) 
1:2000 secondary antibody for 2 h. Immunoreactive bands were, after several washes, 
visualized using LumiLight plus western blotting substrate (Roche Diagnostics, 
Mannheim, Germany). The quantifications were determined by ImageQuant RT ECL. 
Sample values were quantified using a blotting standard curve with known amounts of 
NRG. 
2.3.3 In vitro bioactivity assay 
The bioactivity of NRG released from particle scaffolds was evaluated in vitro by 
determining the proliferative capacity of H9c2 cells after NRG treatment. H9c2 cells 
obtained from embryonic BD1X rat heart tissue were cultured in DMEM medium 
supplemented with 10% FBS, 1% glutamine and 1% penicillin/streptomycin at 37 °C 
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under 5% CO2/95% air [35-37]. Cells were subcultured when 60% confluency was 
achieved. In order to quantify cell proliferation after NRG stimulation, cells were 
seeded in 96-well tissue culture plates at a density of 2 × 103 cells/well. After 24 h, 
medium was removed and the cells were incubated with 150 ng/mL of NRG released 
from particle scaffolds over 24 h, which had previously been quantified by western blot, 
with 150 ng/mL of free NRG or medium alone as control. Culture medium 
supplementation was modified for these experiments by reducing the FBS to 5 % in the 
culture medium. Treatments were removed every day, and fresh treatment was added to 
the cells. After three days of treatments, the number of viable cells was determined by 
MTT assay. Statistics were calculated with Prism 5.0 software (Graphpad Software Inc., 
San Diego, CA, USA). The differences among treatment groups were assessed by 
ANOVA with a Tukey post hoc correction when the values measured were normally 
distributed  
2.4 Isolation and culture of ADSC cells 
ADSC cells were obtained by in vitro culture of the stromal vascular fraction 
(SVF) isolated from inguinal adipose tissue of male Sprague-Dawley transgenical rats 
that expressed the green fluorescent protein (GFP), as previously described [38]. ADSC 
cells were cultured in α-MEM medium supplemented with 10% FBS, 1 ng/mL bFGF 
and 1% penicillin/streptomycin. Cells were subcultured when 80% confluence was 
reached.  
2.5 Adhesion of ADSC cells to particle scaffold 
To favor cell attachment to the MP surface, the particle scaffold was overlaid with 
0.5 μg/cm2 of type 1 collagen and/or PDL [18]. Particle scaffold coating was performed 
in 15 mL falcon tubes. Scaffolds were re-suspended in DPBS and the mixture was 
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sonicated until the particles were completely dispersed in the liquid. Then, coating 
solutions were added to the falcon tube and mixed with the particles under rotation at 37 
ºC for 2 h. Coated particle scaffolds were washed 3 times with distilled sterile water and 
lyophilized for long term storage. For ADSC adhesion, coated MP were resuspended 
with complete α-MEM medium, and were ultrasounded and briefly vortexed prior to 
addition of 2,5 X 105 or 5 X 105 cells. The mixture was then gently flushed and plated 
in Costar® Ultra Low Cluster Flat Bottom Sterile Polystyrene Plate. Plates were 
incubated at 37 ºC for 4 h. At different times cells were observed to study the evolution 
of the adhesion.  
2.6 Determination of dispersability and injectability of ADSC adhering to particle 
scaffold  
Particles with adhered ADSC cells were dispersed in two resuspension medium 
consisting of: (1) 0.1% (w/v) carboxymethyl-cellulose, 0.8% (w/v) polysorbate 80 and 
0.8% (w/v) mannitol in PBS, pH 7.4 and (2) 0.4% (w/v) carboxymethyl-cellulose, 3.2% 
(w/v) polysorbate 80 and 3.2% (w/v) mannitol in PBS, pH 7.4. The dispersing media 
were sterilized by autoclaving prior to use. The suspension injectability was assessed by 
the ability of the particles combined with ADSC to pass through different needles (23, 
24, 25, 27 and 29 gauge (G) needles). 
2.7 In vivo studies using chronic myocardial infarction model 
All animal procedures were approved by the University of Navarra Institutional 
Committee on Care and Use of Laboratory Animals as well as the European 
Community Council Directive Ref. 86/609/EEC. 
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2.7.1 Induction of myocardial infarction 
A total of 26 female Sprague-Dawley rats (Harlan-IBERICA, Spain) underwent 
permanent occlusion of the left anterior descending coronary artery, as previously 
described [11]. Briefly, rats were anesthetized with 4% isoflurane in an induction 
chamber and supported with a mechanical ventilator. Prior to surgery, animals received 
analgesic drug ketoprofen 5 mg/Kg subcutaneously. The rats were then intubated and 
1.5–2% isoflurane was maintained for continuous anesthesia. The heart was accessed 
through a left thoracotomy through the fourth intercostal space, and the left anterior 
descending coronary artery was permanently occluded 2–3 mm distal from its origin. 
The chest was then closed in layers and rats allowed to recover on a heating pad.  
2.7.2 Intramyocardial implantation  
Seven days post-myocardial infarction, rats were placed into the following 
groups: (Group 1)  2.5 x 105 ADSCs-0.75 mg of particle scaffold coated with 0.5 
µg/cm2 of collagen in 100 µL of resuspension medium, (Group 2) 5 x 105 ADSCs-0.75 
mg of particle scaffold coated with 0.5 µg/cm2 of collagen in 100 µL of resuspension 
medium, (Group 3) 5 x 105 ADSCs-0.75 mg of particle scaffold coated with 0.5 µg/cm2 
of mixture of collagen and poly-D-lysine (1:1) in 100 µL of resuspension medium, 
(Group 4)  5 x 105 ADSCs-0.75 mg of NRG-releasing particle scaffold coated with 0.5 
µg/cm2 of mixture of collagen and poly-D-lysine (1:1) in 100 µL of resuspension 
medium and (Group 5)  100 µL of resuspension medium. Two animals in groups 1, 2 
and 3 were injected with rhodamine B fluorescent particle scaffolds to visualize 
particles by fluorescent microscopy. All the treatments were injected in 4 sites of the 
border zone surrounding the infarct zone using a 23 G needle. After treatment injection, 
the chest was closed and rats were allowed to recover on a heating pad.  
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2.7.3 Histological assessment of myocardial tissue after treatment implantation 
Two weeks after treatment implantation, animals were sacrificed and hearts were 
collected for histology. After being harvested, the hearts were perfused-fixed in 4% 
paraformaldehyde at 4 °C, and sliced in three 4-mm-thick segments from apex to base. 
The hearts were dehydrated in ethanol 70% at 4 °C, embedded in paraffin and 5-μm-
sections were cut. Hematoxylin–eosin (HE) staining was performed to visualize tissue 
structure and to study tissue retention of implanted treatment.  
2.7.4 Verification of NRG-releasing particle scaffold retention in the infarcted tissue 
and ADSC cell fate 
Fluorescence microscopy was used to evaluate tissue retention of rhodamine 
particle scaffold and the fate of the ADSCs cells. 
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3 Results and Discussion  
3.1 Characterization of NRG-releasing particle scaffold prepared by TROMS 
3.1.1 Particle size 
NRG-releasing particle scaffolds were successfully prepared by W1/O/W2 
emulsion/extraction method using TROMS technology. The mean particle size 
measured by laser diffractometry was distributed around a mean size of 20 ± 5 µm, with 
a range of 2 to 70 μm. As can be seen in Fig. 1A, particle scaffolds size distribution 
confirms that TROMS allows the obtention of reproducible batches of MP of a desired 
particle size.  
MP with a size of 20 µm were selected as scaffolds for ADSCs. The particle size was 
chosen on the basis of previous research by our group in cardiac regeneration [8, 9, 11], 
where particles with different size were prepared and characterized to select the most 
suitable size for intramyocardial administration of GF [9]. In the present paper a slight 
modification in the particle size was made considering a balance between having 
sufficient surface for cell adhesion and not causing damage to the heart. The best device 
settings to obtain 20 µm particles were: 20 mL/min as pumping flow, 90 s and 60 s as 
recirculation times for obtaining homogeneous W1/O and W1/O/W2 emulsions 
respectively and 0.17 mm and 0.5 mm as needles inner diameter of needles also for 
respectively W1/O and W1/O/W2 emulsion formation.  
3.1.2 Encapsulation efficiencies 
NRG was efficiently encapsulated in 20 µm particle scaffolds reaching encapsulation 
efficiency values of 92.58 ± 3.84%, which corresponds to a final loading of 1851.50 ± 
38 ng of NRG per mg of polymer. This amount of loaded NRG is suitable for in vivo 
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studies [11]. Modifications in the preparation process resulted in 25% higher 
encapsulation efficiencies than those prepared before. The high NRG entrapment 
achieved could be related to the encapsulation method and to the use of TROMS to 
prepare the multiple emulsion system. On the one hand, the water/oil/water evaporation 
technique has been described as resulting in extremely efficient loading of 
biodegradable microparticles with hydrophilic compounds [39, 40] and, on the other 
hand, higher encapsulation efficiencies were found using TROMS compared to 
conventional encapsulation techniques. For instance, for VEGF, an encapsulation 
efficiency of 83.8 % was achieved using TROMS [8]. In contrast, King et al. reported 
an entrapment efficiency of 16 % using the solid/single emulsion/ solvent extraction 
technique to prepare the microparticles [41]. 
NRG is a GF involved in cardiac repair after MI that deserves special attention in heart 
regeneration [12]. Multiple in vivo studies have established the therapeutic potential of 
this cytokine after MI. NRG administration after myocardial injury improved systolic 
function, reduced infarct size and attenuated myocardial hypertrophy in small and large 
animal models of MI [12]. Its beneficial effects might be due to myocyte protection 
from death stimuli and through repair of dysfunctional cardiac myocytes [12]. Several 
clinical trials to evaluate the effect of NRG in humans are ongoing. However, cytokine 
therapy efficacy is generally hindered for the short plasma half live, gastrointestinal 
tract instability and low bioavailability of proteins. Thus, the development of a DDS 
able to release NRG in a sustained manner would improve its potential and efficacy. 
3.1.3 In vitro bioactivity assay 
The bioactivity of encapsulated NRG released from the particle scaffolds was 
evaluated in vitro by determining its capacity to induce H9c2 proliferation (Fig. 1B). 
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The daily addition of NRG released from particle scaffolds (150 ng/mL) induced a 
statistically significant 1.24 fold increase in the proliferation of H9c2 in comparison 
with control (culture medium without cytokine) after 3-day treatment. The increase was 
similar to that observed when H9c2 cells were cultured with the daily addition of free 
NRG for 3 days at doses of 150 ng/mL indicating that the biological activity of NRG 
was maintained after encapsulation and release from particle scaffolds prepared by 
TROMS. 
3.2 Adhesion of ADSC to NRG-releasing particle scaffold 
The development of a DDS able to protect NRG from degradation and to ensure 
its sustained release throughout time would reinforce NRG efficacy in cardiac repair as 
it was mentioned before in this section. Moreover, in the present work we move one 
step forward combining NRG DDS with ADSC able to secrete multiple cytokines 
involved in cardiac regeneration. Interestingly, this is the first report of NRG-releasing 
scaffold for cardiac tissue engineering applications. The importance of multiple growth 
factor action in cardiac tissue regeneration has been extensively described [19, 21, 42]. 
In this regard, the possibility of increasing the beneficial effect obtained with NRG 
releasing particles combining this DDS with several other cytokines secreted by SC 
would open up new possibilities in heart regeneration. Among SC, ADSC are 
particularly suitable for cell therapy because of their easy isolation from the stromal 
vascular fraction [29-32], their extensive differentiation potential and the secretion of 
several angiogenic and anti-apoptotic factors that activate the revascularization process 
and the positive remodeling of the heart [31, 33]. Although it is known that ADSC exert 
their positive effect via paracrine secretion, the beneficial factors remain partly 
unidentified. Moreover, it is possible that multiple factors might be functioning 
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synergistically [43-45]. For that reason, ADSC transplantation for their paracrine effects 
still represents a reasonable strategy. In addition, SC are able to sense and respond to 
changes in the host environment modifying its paracrine secretion. Moreover, until now, 
NRG secretion by ADSC has not been described, meaning that the association of these 
two strategies might have complementary effects on cardiac tissue repair. 
In the present study, the adhesion of 2,5 X 105 or 5 X 105 ADSC to particle scaffolds 
coated with different concentrations of collagen and PDL was studied. The 
concentration that showed better adherence was 0.5 μg/cm2, either with the collagen or 
the mixture of collagen and PDL (1:1). The administration of these amounts of cells 
induced an improvement in the cardiac function when administered in combination with 
collagen-based carrier sheets after MI [26]. On the other hand, the dose of NRG 
administered with that quantity of MP also promoted cardiac repair and improved 
cardiac performance.  
Both cell densities adhered efficiently to all particle scaffolds assayed. Observations of 
cell adhesion over time indicated that collagen coated particle scaffolds required 4 h for 
total cell attachment while particle scaffolds coated with collagen and PDL attached to 
the cells after 2 h (Fig. 2). Differences in cell adhesion time might be due to collagen 
and PDL net charge at pH value of the culture medium used for adhesion (pH 7.2). 
Thus, collagen net charge at pH 7.2 is negative due to its isoelectric point of 5.5, 
hindering cell adhesion. On the other hand, PDL with an isoelectric point of 12.9, has a 
net charge positive at pH 7.2 that favors the adhesion of the cells. As in the coating and 
adherence processes a certain amount of encapsulated NRG is released over time, the 
less time required for ADSC NRG-particle scaffold preparation, the less amount of 
NRG would be lost during the manufacture process.  
17 
 
The use of biodegradable microparticles as injectable scaffolds for tissue engineering 
applications was first proposed by Montero-Menei C. N. and colleagues [46, 47]. After 
that, several authors investigated their potential to improve cell survival and 
differentiation [18-20, 22-24, 48]. The differentiation of ADSC towards a cardiac 
lineage is, however, not the main objective of the present research. ADSC cells were 
combined with NRG delivery systems for their beneficial paracrine effect on 
endogenous cells. Thus, a multidrug delivery system able to respond to the surrounding 
tissue would be obtained. 
3.3 Dispersability and injectability of NRG-releasing particle scaffold combined 
with ADSC 
The injection of ADSC-particle scaffolds in the infarcted heart required the 
selection of a good dispersing medium that allows the cell-particle scaffold suspension 
to pass through a needle without needle blockage or sedimentation. A cell-particle 
scaffold suspension with good rheological properties will ensure dose uniformity and 
safety requirements during the local myocardial injection of the treatments. Two 
dispersing media containing different percentages of DMEM, carboxymethyl-cellulose, 
polysorbate 80 and mannitol were investigated in the present study. These excipients are 
included in the Handbook of Pharmaceutical Excipients [49] and are frequently used in 
commercial formulations. DMEM is a solution commonly used for drug/cell injection 
into the infarcted heart [50, 51], carboxymethyl-cellulose is a  wetting and 
biocompatible agent that prevent particle aggregation and makes their injection through 
a thin needle and polysorbate 80 and mannitol has been previously used to suspend 
PLGA microparticles prior to intracerebral implantation [34]. The ADSC particle 
scaffold suspension showed the best flow properties in the dispersing medium 
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containing 0.4% (w/v) carboxymethyl-cellulose, 3.2% (w/v) polysorbate 80 and 3.2% 
(w/v) mannitol in PBS, pH 7.4. No toxicity or cell detachment was observed when using 
this medium.  
Prior to injection in the infarcted myocardium, the injectability of the cell-particle 
scaffold suspension was analyzed. To this end, ADSCs adhered to 20 µm particle 
scaffolds were delivered through needles with different diameter (23, 24, 25, 27 and 29 
G). ADSC particle scaffolds were only able to go through the 23G needle without 
blocking or sedimentation, and carrying ADSC cells adhered on the surface. This needle 
was therefore used for intramyocardial administration (Fig. 3).  
3.4 Histological evaluation of myocardial tissue after the injection of NRG-
releasing particle scaffold combined with ADSC 
Finally, ADSC combined with empty or cytokine delivery systems coated with 
collagen or collagen:PDL were intramyocardially injected in the infarcted beating heart 
(Fig. 3). Two weeks later, animals were sacrificed to further evaluate myocardial tissue 
reaction and the non-toxic properties of the implanted scaffold in vivo. Upon 
implantation, hematoxylin and eosin staining revealed that ADSC particle scaffolds 
were well tolerated by the infarcted myocardium and they seem to integrate well within 
the host tissue (Fig. 4 C,D). Heart response after ADSC-scaffold injection was the 
typical reaction observed following mechanical trauma and exposure to a foreign body. 
ADSC-scaffolds (Fig. 4 C,D) did not induce inflammatory reactions when compared to 
resuspension medium injection (Fig. 4 A,B). Hematoxilin and eosin staining did not 
evidence noticeable differences in terms of biocompatibility and local tolerance between 
groups. Moreover, the tissue adjacent to the implanted treatments maintained its 
physiological characteristics and no adverse cellular reactions were observed.  
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3.5 Confirmation of NRG-releasing particle scaffold retention in the infarcted heart 
and ADSC cell fate 
Fluorescent and brightfield microscopy showed that two weeks after 
intramyocardial implantation, particle scaffolds appeared grouped at the implantation 
site independently of the coating used to attach ADSC (Fig. 4 C,D and 5 A,B). At day 
14, particle scaffolds were not totally biodegraded and a significant quantity of them 
were still detectable. No differences in terms of scaffold degradation were observed 
among the various groups during the two-week implantation period. As can be seen in 
Figure 4 C,D and 5 A,B, counterstaining of nuclei revealed that particle scaffolds were 
always surrounded by cells suggesting that ADSC remained attached to the particle 
scaffold.  
Taking together our in vitro ADSC adhesion studies and our present in vivo 
biocompatibility findings on infarcted rats, 5 X 105 ADSC cells combined with NRG-
releasing particle scaffolds coated with collagen and PDL will be selected to further 
assess the therapeutic potential of this strategy in cardiac regeneration.  
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Conclusion 
The data presented is this article offers valuable evidence of the feasibility of 
using NRG-releasing particle scaffolds combined with ADSC as a multi GF delivery-
based tissue engineering strategy to treat the ischemic heart. Future studies will be 
focused on the response produced by the treatment, to demonstrate whether the 
combination of ADSC with NRG and using particle scaffolds as support is helpful in 
the regeneration of the infarcted heart.  
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Figure captions 
Figure 1: Nrg-releasing particle scaffold characterization. A) Representative particle 
size distribution measured by laser diffractometry of Nrg-releasing particle scaffold 
prepared by TROMS. B) H9c2 proliferation induced by Nrg stimulation (free or 
released from particle scaffold at 150 mg/mL) (y axis represents fold increase vs 
negative control). *p< 0.05, ***p< 0.001 
Figure 2: Representative images showing (A) bright field and (B) fluorescence images 
of ADSC combined with Nrg-releasing particle scaffolds shortly before intramyocardial 
implantation in the peri-infart area. Scale bars: 50 µm. 
Figure 3: Macroscopic view of the infarcted heart following ADSC combined with 
Nrg-releasing particle scaffold implantation. Seven days after LAD coronary artery 
occlusion, ADSC combined with Nrg-releasing particle scaffolds were injected into the 
peri-infarct zone through a 1-mL insulin syringe with a 23-G needle while the heart was 
beating. Note the presence of the ADSC-scaffold in the beating heart demonstrating that 
ADSC-scaffolds were not washed out from the infarcted myocardium. 
Figure 4: Histological evaluation of myocardial tissue reaction 14 days after ADSC 
combined with Nrg-releasing particle scaffold administration in hematoxylin-eosin 
stained sections. The administration of ADSC combined with Nrg-releasing particle 
scaffold was well tolerated by the tissue and no differences in tissue inflammation were 
found between the administration of medium (A, B) or ADSC combined with Nrg-
releasing particle scaffold (C, D). At higher magnifications, the ADSC-scaffold 
(indicated by asterisk) were much more clearly visualized (D). Scale bars: 1000 µm (A, 
C) and 200 µm (B, D). 
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Figure 5: ADSC-scaffold visualization in the heart tissue. ADSC combined with Nrg-
releasing particle scaffold (indicated by asterisk) were clearly visualized in the peri-
infart area that encompassed the infart zone on day 14 after implantation by 
fluorescence microscopy. Nuclear staining was performed with DAPI (blue). Scale bars: 
100 µm (A) and 30 µm (B). 
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Graphical abstract. Results of this work demonstrated the potential value of ADSC 
cells combined with NRG delivery systems for cardiac tissue engineering. The two most 
relevant findings of this study were as follows: (1) ADSC were efficiently attached to 
NRG-releasing particles in vitro (A, B) and (2) the ADSC-cytokine delivery system 
injected in the infarcted heart (C) proved to be compatible with an intramyocardial 
administration in terms of injectability through a 23-gauge needle and tissue response 
(D, E). Taken together, this proof of concept study provides important evidences 
required for future effectiveness studies and for the translation of this approach to the 
context of cardiac regeneration. 
 
 
